{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:41:12Z","timestamp":1770507672224,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.vaccine.2008.08.050","type":"journal-article","created":{"date-parts":[[2008,9,18]],"date-time":"2008-09-18T17:01:49Z","timestamp":1221757309000},"page":"5922-5927","source":"Crossref","is-referenced-by-count":122,"title":["First administration to humans of a monoclonal antibody cocktail against rabies virus: Safety, tolerability, and neutralizing activity"],"prefix":"10.1016","volume":"26","author":[{"given":"A.B.H.","family":"Bakker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Python","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.J.","family":"Kissling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.E.","family":"Marissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.F.","family":"Brink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Lagerwerf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Worst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"van Corven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kostense","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.J.","family":"Weverling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Uytdehaag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.J.","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.E.","family":"Rupprecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Goudsmit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"49\/50","key":"10.1016\/j.vaccine.2008.08.050_bib1","first-page":"425","article-title":"WHO position paper","volume":"82","author":"Rabies vaccines","year":"2007","journal-title":"Wkly Epidemiol Rec"},{"issue":"52","key":"10.1016\/j.vaccine.2008.08.050_bib2","doi-asserted-by":"crossref","first-page":"8647","DOI":"10.1016\/j.vaccine.2007.10.004","article-title":"An important date in rabies history","volume":"25","author":"Dodet","year":"2007","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2008.08.050_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1473-3099(02)00287-6","article-title":"Rabies re-examined","volume":"2","author":"Rupprecht","year":"2002","journal-title":"Lancet Infect Dis"},{"issue":"25","key":"10.1016\/j.vaccine.2008.08.050_bib4","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1056\/NEJMcp042140","article-title":"Clinical practice. Prophylaxis against rabies","volume":"351","author":"Rupprecht","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2008.08.050_bib5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1086\/324628","article-title":"Postexposure treatment of rabies infection: can it be done without immunoglobulin?","volume":"34","author":"Wilde","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"16","key":"10.1016\/j.vaccine.2008.08.050_bib6","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1016\/j.vaccine.2005.10.015","article-title":"Preventing the incurable: Asian rabies experts advocate rabies control","volume":"24","author":"Dodet","year":"2006","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.vaccine.2008.08.050_bib7","doi-asserted-by":"crossref","first-page":"7605","DOI":"10.1016\/j.vaccine.2007.08.054","article-title":"Failures of post-exposure rabies prophylaxis","volume":"25","author":"Wilde","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.08.050_bib8","unstructured":"WHO. WHO consultation on a rabies monoclonal antibody cocktail for rabies post exposure treatment. Geneva: WHO, 23\u201324; May 2002. http:\/\/www.who.int\/rabies\/vaccines\/en\/mabs_final_report.pdf 2002."},{"issue":"14","key":"10.1016\/j.vaccine.2008.08.050_bib9","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1128\/JVI.79.14.9062-9068.2005","article-title":"Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants","volume":"79","author":"Bakker","year":"2005","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2008.08.050_bib10","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1128\/JVI.79.8.4672-4678.2005","article-title":"Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis","volume":"79","author":"Marissen","year":"2005","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2008.08.050_bib11","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1086\/500470","article-title":"Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin","volume":"193","author":"Goudsmit","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2008.08.050_bib12","unstructured":"Current WHO guide for rabies pre- and post-exposure treatment in humans. WHO; 2002."},{"key":"10.1016\/j.vaccine.2008.08.050_bib13","series-title":"Laboratory techniques in rabies","first-page":"181","article-title":"A rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus-neutralizing antibody","author":"Smith","year":"1996"},{"issue":"1","key":"10.1016\/j.vaccine.2008.08.050_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijid.2005.10.007","article-title":"Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey","volume":"11","author":"Sudarshan","year":"2007","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2008.08.050_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/biol.1997.0117","article-title":"Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies","volume":"26","author":"Lang","year":"1998","journal-title":"Biologicals"},{"issue":"4","key":"10.1016\/j.vaccine.2008.08.050_bib16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s15010-007-6277-7","article-title":"Adverse effects of rabies pre- and postexposure prophylaxis in 290 health-care-workers exposed to a rabies infected organ donor or transplant recipients","volume":"35","author":"Mattner","year":"2007","journal-title":"Infection"},{"issue":"11","key":"10.1016\/j.vaccine.2008.08.050_bib17","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.vaccine.2004.09.013","article-title":"Adverse reactions to human rabies immune globulin manufactured by the Thai Red Cross Society","volume":"23","author":"Suwansrinon","year":"2005","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2008.08.050_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0001-706X(99)00092-3","article-title":"Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPRV): a two-stage randomised clinical trial in the Philippines","volume":"75","author":"Quiambao","year":"2000","journal-title":"Acta Trop"},{"issue":"1","key":"10.1016\/j.vaccine.2008.08.050_bib19","first-page":"36","article-title":"Ten year longitudinal study of efficacy and safety of purified chick embryo cell vaccine for pre- and post-exposure prophylaxis of rabies in Indian population","volume":"27","author":"Sehgal","year":"1995","journal-title":"J Commun Dis"},{"issue":"18","key":"10.1016\/j.vaccine.2008.08.050_bib20","first-page":"6851","article-title":"Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33","volume":"61","author":"Ritter","year":"2001","journal-title":"Cancer Res"},{"issue":"RR-1","key":"10.1016\/j.vaccine.2008.08.050_bib21","first-page":"1","article-title":"Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"48","author":"Human rabies prevention\u2014United States","year":"1999","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"10.1016\/j.vaccine.2008.08.050_bib22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0001-706X(98)00038-2","article-title":"Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine","volume":"70","author":"Lang","year":"1998","journal-title":"Acta Trop"},{"issue":"5","key":"10.1016\/j.vaccine.2008.08.050_bib23","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/infdis\/145.2.720","article-title":"Antibody responses to human diploid cell vaccine for rabies with and without human rabies immune globulin","volume":"145","author":"Mertz","year":"1982","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2008.08.050_bib24","first-page":"115","article-title":"Studies with human diploid cell strain rabies vaccine and human antirabies immunoglobulin in man","volume":"40","author":"Nicholson","year":"1978","journal-title":"Dev Biol Stand"},{"issue":"13","key":"10.1016\/j.vaccine.2008.08.050_bib25","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1001\/jama.217.13.1825","article-title":"Rabies immune globulin (human). Clinical trials and dose determination","volume":"217","author":"Loofbourow","year":"1971","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vaccine.2008.08.050_bib26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0092-1157(89)90032-2","article-title":"Intravenous human rabies immunoglobulin for post-exposure prophylaxis: serum rabies neutralizing antibody concentrations and side-effects","volume":"17","author":"Aoki","year":"1989","journal-title":"J Biol Stand"},{"issue":"5","key":"10.1016\/j.vaccine.2008.08.050_bib27","first-page":"491","article-title":"Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group","volume":"76","author":"Lang","year":"1998","journal-title":"Bull World Health Org"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08012036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08012036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T15:52:48Z","timestamp":1545753168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X08012036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":27,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0264410X08012036"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2008.08.050","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}